AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01492985 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebos of GTU-multiHIV B and LIPO-5 vaccines
Description: Placebos corresponds respectively to 1X PBS pH = 7.2 and glucose 5%
Study NCT01492985 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GTU-multHIV B vaccine and LIPO-5 vaccine
Description: Vaccines are respectively an HIV-DNA plasmid and a mixture of 5 HIV-lipopeptides.
Study NCT01090271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Isokinetic eccentric training
Description: The eccentric training for the shoulder abductors was performed for 6 consecutive weeks, twice a week, on alternate days.
Study NCT03005067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbomer 980 (1146A)
Description: Test product containing carbomer 980 gel
Study NCT03005067 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Reference product containing vehicle without carbomer 980 gel
Study NCT01956448 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug eluting stent
Description: Device: Percutaneous intervention with implantation of drug eluting coronary stent (Resolute Integrity)
Study NCT01509482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples
Description: blood samples to test for primary and secondary outcome measures
Study NCT03233633 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Medical Marijuana
Description: oral capsule, high ratio CBD:THC
Study NCT01509482 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples
Description: IR Cholesterol HDL LDL Fasting Glucose Triglycerides
Study NCT04062149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: single leg stance treatment
Description: SLS treatment following the neurodevelopmental treatment (NDT). SLS is the ability of one limb to support the body's weight in a standing position. In gait it is the foot being in contact with the ground whilst the body passes over it and this stance phase of gait accounts for 60% of the gait cycle. The treatment approach of NDT has been chosen as this is the most common physiotherapy treatment option in the UK and is the most common option in the studies above. NDT is a problem-solving approach to the assessment and treatment of individuals with disturbances of function, movement and postural control due to a lesion of the central nervous system and provides an outline of the treatment required to achieve SLS which will form the basis of the intervention of this study.
Study NCT04062149 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual physiotherapy
Description: Individualised physiotherapy treatment approach, as per standard protocol, but it will not work specifically on SLS. Will be based on the neuro-developmental technique.
Study NCT02508038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TCRαβ+/CD19+ depleted Haploidentical HSCT
Description: Patients with high-risk leukemia will receive myeloablative conditioning. All other patients will undergo a reduced-intensity conditioning with ATG, Fludarabine, Thiotepa and Melphalan followed by transplant with a KIR/KIR (Killer cell immunoglobulin-like recetptor) ligand mismatched haploidentical donor peripheral blood stem cell graft depleted of TCRab+ cells and CD19+ cells using the CliniMACS System.
Study NCT02508038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronate
Description: Given IV. Patients will receive five doses of Zoledronate (each 1.25 mg/m2 at a 28 day interval) following transplant.
Study NCT01996059 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional Jejunal Interposition
Description: First, an end-to-side esophagojejunostomy was performed at 40 cm anal to Treitz's ligament. Then, an end-to-side duodenojejunostomy was created at the efferent limb 35 cm distal to the esophagojejunostomy, followed by a side-to-side jejunostomy at 5 cm distal to duodenojejunostomy and 20 cm distal to Treitz's ligament. Finally, 2 jejunal proper ligations were made at 5 cm oral to esophagojejunostomy and 2 cm distal to duodenojejunostomy.
Study NCT02794571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 200 mg/m\^2 IV infusion will be administered on Day 1 of each 21-day cycle after combination treatment with atezolizumab and tiragolumab.
Study NCT02794571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100 mg/m\^2 IV infusion will be administered on Days 1, 2, and 3 of each 21-day cycle with combination treatment of atezolizumab and tiragolumab.
Study NCT04548830 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transbronchial cryobiopsy
Description: After enrollment, and pre-treatment procedures are complete, patients will undergo flexible bronchoscopy with a therapeutic bronchoscope under general anesthesia via an advanced airway at Memorial Hospital in an inpatient or outpatient setting.
Study NCT02794571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1250 mg/m\^2 oral dose will be administered twice daily (BID) on Days 1 through 14 of each 21-day cycle. On Day 1 of Cycle 1, the first dose of capecitabine will be administered prior to the atezolizumab and tiragolumab infusion.
Study NCT02794571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg IV infusion will be administered on Day 1 of each 21-day cycle after combination treatment of atezolizumab and tiragolumab.
Study NCT02794571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV infusion will be administered on Day 1 of each 21-day cycle after treatment with tiragolumab.
Study NCT01996059 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y
Description: The distal end of the duodenum was closed. The jejunum was separated 15-20cm distal to the Treitz's ligament, and an end-to-side esophagojejunostomy was done at the distal side of the jejunum. Then, the continuity of the jejunum was reconstructed with side-to-end jejunojejunostomy at 40-45cm distal to esophagojejunostomy.
Study NCT00821002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost
Description: Comparison of punctal plug placement between upper and lower puncta
Study NCT04267445 — intervention group
Intervention type: PROCEDURE
Intervention: Embolization of prostatic artery under ultrasound guidance
Description: Ekobi Embolization MIcrospheres is administered via selective angiography and Prostatic Artery Embolization (PAE), a minimally invasive technique for reducing symptoms from Benign Prostatic Hyperplasia (BPH) to achieve near stasis in the target vasculature. Contrast Enhanced Ultrasound (CEU) and angiographic runs will be used to confirm anatomy at the time of embolization.
Study NCT01442987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan/Atorvastatin A
Description: once daily, P.O. 8week
Study NCT01442987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: once daily, P.O. 8week
Study NCT01442987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin A
Description: once daily, P.O. 8week
Study NCT01442987 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily, P.O. 8week
Study NCT01442987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan/Atorvastatin B
Description: once daily, P.O. 8week
Study NCT01442987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin B
Description: once daily, P.O. 8week
Study NCT03695445 — intervention group
Intervention type: DRUG
Intervention: Peripheral administration of Norepinephrine
Description: Systematic follow-up of complications from peripheral administration of Norepinephrine
Study NCT03822026 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hyperventilation test
Description: Increase of the alveolar ventilation by a stepwise increase in tidal volumes and respiratory rate until a reduction of end-tidal CO2 of 0.7 kPa is achieved
Study NCT00543985 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stress Echocardiography
Description: Echocardiography was performs prior to and within 60 seconds of completing the standard Bruce treadmill protocol.
Study NCT03711994 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alkantis
Description: cold therapy pack placed on the wound post operatively
Study NCT01347060 — intervention group
Intervention type: DRUG
Intervention: fluticasone propionate/salmeterol xinafoate combination
Description: Fluticasone propionate/salmeterol xinafoate combination for asthma, all doses (100mcg/50mcg, 250 mcg/50mcg and 500 mcg/50mcg)
Study NCT01347060 — intervention group
Intervention type: DRUG
Intervention: inhaled corticosteroids
Description: Inhaled corticosteroids: beclomethasone dipropionte, mometasone, fluticasone propionate, budesonide, and flunisolide
Study NCT02893891 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy
Description: Sleeve gastrectomy involves removing most of the stomach, limiting the amount of food the patient can eat.
Study NCT02893891 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic gastric plication
Description: Laparoscopic gastric plication involves sewing one or more large folds in the stomach. During the laparoscopic gastric plication, the stomach volume is reduced about 70%, which makes the stomach able to hold less and helps the patient eat less.
Study NCT02893891 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intragastric balloon
Description: The introduction of the balloon is non-invasive as it is inserted endoscopically (down the oesophagus). The balloon is then filled inside the stomach with a dyed physiological solution, which reduces the volume of the stomach.
Study NCT02893891 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intragastric balloon implantation
Description: Intragastric balloons (End-Ball, Medsil) will be implanted in the patients with morbid obesity.
Study NCT05358002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Frontalis flap
Description: Fashonizing a flap from frontalis muscle and connecting it to the tarsus of the upper eyelid
Study NCT05358002 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Frontalis flap
Description: Fashonizing a flap from frontalis muscle and connecting it to the tarsus of the upper eyelid
Study NCT03526211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES cycling
Description: On the patient, three pairs of electrodes will be applied on tibial hamstring, quadriceps and gluteal muscles of each lower limb. Cycloergometer will be installed in passive mode. Then, optimal stimulation intensity for each muscle will be defined. During twenty minutes, neuromuscular electrical stimulation will generate a passive pedaling on cycloergometer.
Study NCT02996929 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LC System
Description: Subjects will undergo CIED lead extraction with the LC system
Study NCT01349114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aliskiren 300 mg once daily
Description: aliskiren 300 mg daily
Study NCT01349114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/sugar pill
Description: Sugar pill/placebo
Study NCT04470765 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zida
Description: Transcutaneous Tibial Nerve Stimulation
Study NCT04470765 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Zida
Description: Transcutaneous Tibial Nerve Stimulation
Study NCT02152748 — intervention group
Intervention type: GENETIC
Intervention: analyze systematically morphological and molecular changes associated with glioblastoma progression and therapy-resistance
Study NCT00125788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-glutamine
Description: Approximately 0.3 g/kg total daily dose of L-glutamine will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
Study NCT00125788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Approximately 0.3 g/kg total daily dose of maltodextrin placebo will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
Study NCT03187912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: Riboflavin with 20% Dextran or HPMC will be admininstered every 2 minutes for overall 30 minuts (Dextran) or 10 minutes (HPMC), respectively
Study NCT02065596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: the study will begin with enrollment of an initial safety cohort of at least 10 subjects at the lowest dose, after which enrollment will pause until the dose-limiting toxicity (DLT) period has been completed. If a patient experiences DLT, defined as failure to engraft. In which case, the patient may be advanced to two higher doses.
Study NCT02065596 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Transplant (HSCT)
Description: Three weeks after Immunomodulation patients will be infused with matched bone marrow from a sibling, unrelated donor, haploidentical donor, or cord blood. Patients will be followed for the following year.
Study NCT02397694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIC
Description: 75 mg tablet administered orally once daily
Study NCT02397694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF
Description: 200/25 mg FDC tablet administered orally once daily
Study NCT02397694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: F/TAF
Description: 200/25 mg FDC tablet administered orally once daily
Study NCT02397694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DTG
Description: 50 mg tablet administered orally once daily
Study NCT02397694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIC Placebo
Description: Tablet administered orally once daily
Study NCT02397694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG Placebo
Description: Tablet administered orally once daily
Study NCT02397694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg FDC tablet administered orally once daily
Study NCT02397694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B/F/TAF
Description: 50/200/25 mg FDC tablet administered orally once daily
Study NCT00834704 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PEGPH20
Description: PEGylated recombinant human hyaluronidase
Study NCT00424528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arformoterol Tartrate Inhalation Solution
Description: Arformoterol tartrate inhalation solution 15 mcg twice daily and placebo inhalation powder once daily.
Study NCT00424528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Placebo inhalation solution twice daily and tiotropium inhalation powder 18 mcg once daily.
Study NCT00424528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arformoterol and Tiotropium
Description: Arformoterol tartrate inhalation solution 15 mcg twice daily and Tiotropium inhalation powder 18 mcg once daily.
Study NCT00424528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo inhalation solution and placebo inhalation powder
Study NCT01734980 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial Ultrasound
Description: The samples will be divided as 2 groups for comparison. Group A is the group of samples where we apply negative pressure syringe for needle suction. Group B is where no suction will be applied after needle insertion.
Study NCT03808038 — intervention group
Intervention type: OTHER
Intervention: None- Observational Study
Description: None- Observational Study
Study NCT01916473 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia
Description: Epidural analgesia is provided with ropvacaine 0.2% given 6 hourly
Study NCT01916473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous wound infusion
Description: Continuous wound infusion via catheter
Study NCT03067636 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercise
Description: Physical exercise: Amount of time exercising gradually titrated from 90-minutes in week one to 180-minutes in week eight. Intensity titrated concurrently from 40 - 60% VO2 max in week one to 40 - 90% VO2 max in week eight. Eight week gym membership provided to all participants to facilitate engagement in exercise.
Study NCT03348748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03067636 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress management training A
Description: Stress management training A: Daily stress management training for eight weeks with training activity delivered via app. Session lengths titrated from 10-minutes per day in the first week to 20-minutes per day in week eight.
Study NCT03067636 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress management training B
Description: Stress management training B: Daily stress management training for eight weeks with training activity delivered via app. Session lengths titrated from 10-minutes per day in the first week to 20-minutes per day in week eight.
Study NCT03348748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03348748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo lowest-dose of SBRT
Study NCT02862886 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: myometrium biopsy
Study NCT03703115 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fasting
Description: No food for 14 -16 hours with water intake and non caloric beverages then eating balanced meals over 8 to 10 hours
Study NCT00787384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Patients received oral imatinib 100 mg/d; in case of unsatisfactory response (less than complete) Imatinib could be increased by 100 mg/die on a weekly basis and up to a maximum of 400 mg/die. Imatinib wsa discontinued after 12 total weeks of therapy.
Study NCT03348748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo lowest- or higher-dose of SBRT
Study NCT01392443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: INC424 Tablet for oral use, provided in 5 mg bottles. The dosage strength was 5 mg/tablet INC424 phosphate (free base equivalent).
Study NCT03348748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo highest-dose of SBRT
Study NCT03348748 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic Surgical Procedure
Description: Undergo thoracic surgery
Study NCT04036149 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraocular lens
Description: Implantation as part of cataract surgery
Study NCT04036149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraocular lens
Description: Implantation as part of cataract surgery
Study NCT01578668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: 150 mg given orally (po), daily (QD), starting on the 4th day of each cycle, ending on the 21th day before the next cycle, and until disease PD
Study NCT01578668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m² intravenous (iv) over 15 minutes on the first day of each 21-day cycle until disease progression (PD) or unacceptable toxicity or no more than 6 cycles
Study NCT01578668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: cisplatin 20mg/m² iv on the 1st-3rd day (if PS\<2) or 30 mg iv on the 1st-2nd day (if PS=2 or 3)of each cycle until PD or unacceptable toxicity or no more than 6 cycles
Study NCT01578668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: 150 mg given orally (po), daily (QD), starting on the first day of the first cycle
Study NCT03554603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Report
Description: An abbreviated version of the microbiology report indicating that growth is present and the physician should call the lab for further details if clinically important.
Study NCT00917995 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polypropylene Mesh, density 25-40g/square meter
Description: colostomy with a prophylactic hernia mesh
Study NCT02782637 — intervention group
Intervention type: OTHER
Intervention: survey and interview
Description: all participants: survey on prenatal counseling and treatment decisions at the limits of viability.~a selection of participants: individual interviews to further perform in-depth exploration of prenatal counseling preferences
Study NCT01100541 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polymeric plate
Description: Application of the polymeric plate in the shoulder for 20 minutes after warming it for 15 minutes in hot water, initially at boiling temperature.
Study NCT00172809 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a 135 ug/week for 24 weeks
Study NCT00648024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anagrelide Hydrochloride Capsules 1 mg
Description: 1mg, single dose fasting